The Food and Drug Administration has told ultrasound contrast developer Molecular Biosystems of San Diego that it expects to issue a final decision on ultrasound contrast regulation by July 28. The ruling should help clear up a regulatory morass that has
The Food and Drug Administration has told ultrasound contrast developer Molecular Biosystems of San Diego that it expects to issue a final decision on ultrasound contrast regulation by July 28. The ruling should help clear up a regulatory morass that has halted the review of most ultrasound contrast agents (SCAN 4/30/97).
The FDA in April suspended its regulatory review of MBI's Optison agent (formerly known as FS069) in response to citizen's petitions filed by competitors Bracco, Sonus Pharmaceuticals, and ImaRx Pharmaceutical and its partner Du Pont Merck. The FDA also froze its review of agents under development by those companies.
The petitioning companies charge that MBI has received preferential treatment from the FDA because Optison is being regulated by the agency's Center for Devices and Radiological Health, while their products are being reviewed by the Center for Drug Evaluation and Review.
In response to lawsuits filed by the three companies, the FDA was ordered by a U.S. District Court judge to review the merits of the citizen's petitions before proceeding with the review process. Late last month, MBI reported that the FDA has told the company that it expects to issue a final ruling on the matter by the end of this month.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.